Sunday, Nov. 22, 2026 A Vik Media Group publication
Mongevity Longevity in Motion
Leer en español

Lung cancer study maps where CD73 and CD39 sit in tumors

Lung cancerPart of a story we are following · 12 articles · See every update
A family walks along a gravel trail through autumn trees at Natural Bridge State Park.
A family walks along a gravel trail through autumn trees at Natural Bridge State Park.Photo: vastateparksstaff / Wikimedia Commons, CC BY 2.0

If you or someone close to you is facing lung cancer, this is early lab science, and nothing about care changes today. But it gives a detailed picture of where this pathway sits in lung tumors.

In a study of tumor samples from several groups of people with non-small cell lung cancer, plus lab-grown cancer cells, a pathway called CD39/CD73 showed up mostly in lung adenocarcinomas that also had high PD-L1 and many immune T cells. The researchers say the findings can inform how future treatments are designed and who gets them.

How the study worked

The team studied tumor tissue from multiple groups of patients with non-small cell lung cancer, using special microscope methods that light up proteins and read gene activity in place. They also ran experiments on cultured lung cancer cells. The work was published on November 9, 2026 in Cell Reports Medicine. It is lab research on tissue and cells, so it describes what tumors look like and how they react, and it does not yet test whether choosing patients this way changes their results.

Why did researchers look at CD73 and CD39?

Recent clinical trials tested antibodies that block CD73 together with drugs that block PD-L1. In a subset of people with non-small cell lung cancer that could be removed by surgery, the combination showed strong anti-tumor activity. A subset means not everyone responded.

That raises an obvious question: what is different about the tumors where it worked? To answer it, scientists first need a clear picture of where CD73 and its partner CD39 are found in human lung tumors. That is what this study set out to draw.

What they found

The results came in four main parts.

The pathway is not spread evenly. Inside the tumor and the tissue around it, CD39 and CD73 sat in some places more than others. The researchers call this an asymmetric distribution.

Some tumors carry more of it. The pathway showed up preferentially in lung adenocarcinomas, a common type of non-small cell lung cancer. It was more common when PD-L1 was high and when many effector T cells, the immune cells that attack tumors, had moved into the tumor. It was also more common in tumors that lacked changes in two genes, STK11 and KEAP1.

Within one tumor, the picture was fairly steady. The study found limited spatial heterogeneity inside a single tumor. In plain words, one part of a tumor looked reasonably like another part when it came to this pathway. The study did not measure whether this makes tests on small samples more useful.

Treatment and inflammation change it. In the cultured cells, signals that drive inflammation, called proinflammatory cytokines, changed how much CD73 the cancer cells carried. Radiation and chemotherapy given together also changed it, and not in the same way in every case. The study’s title says the pathway is increased by proinflammatory states and modified by chemo-radiation.

The abstract does not give the number of patients or the size of the changes, so there is no single figure to quote here.

What are PD-L1 and STK11/KEAP1?

PD-L1 is a protein on tumors that drugs called PD-L1 antagonists are built to block. Doctors may already check it when planning treatment. STK11 and KEAP1 are genes. A mutation is a change in a gene, and this study found the CD39/CD73 pathway more often in tumors without STK11 or KEAP1 mutations.

You do not need to remember the names. The point is that each tumor has a profile of these markers, and this study describes that profile without testing whether it predicts which treatment suits the tumor.

What you can do today

There is no new step for you to take because of this study. Current advice does not change, and CD73-blocking antibodies are still being tested in trials rather than being a routine option.

If you or a family member is being treated for lung cancer, ask your care team at the next visit what the tumor tests showed, such as PD-L1, and what those results mean for your treatment choices.

For clinicians and researchers

Design: Translational study using multiplexed quantitative immunofluorescence and spatial transcriptomics in multiple human non-small cell lung cancer (NSCLC) patient cohorts, plus in vitro experiments in cultured NSCLC cells. Sample size is not given in the abstract.

Main result: CD39/CD73 showed an asymmetric distribution within the tumor microenvironment and preferential expression in lung adenocarcinomas with elevated PD-L1 and effector T cell infiltration or lacking STK11/KEAP1 mutations. Intratumor spatial heterogeneity was limited. Cancer cell CD73 was differentially modulated by proinflammatory cytokines and systemic radio-chemotherapy.

Main limitation: Descriptive biomarker analysis of tissue and cultured cells; it does not test clinical outcomes or whether CD73 blockade benefits any patient group. Cohort sizes are not reported in the abstract.

Open question: Whether the expression patterns can be used to select patients for CD73-blocking antibodies combined with PD-L1 antagonists, and how radio-chemotherapy sequencing should be designed around CD73 modulation, remain to be tested.

Got a question? Ask us ›

Get the best of longevity science by emailThe most useful new studies, in plain language and with the source. Free.

We'll email you once to confirm. Occasional messages from our sponsors, clearly labeled. Unsubscribe anytime. We never ask for health data.
Cite this article
AMA
Mongevity Desk. Lung cancer study maps where CD73 and CD39 sit in tumors. Mongevity. Published November 22, 2026. Accessed November 22, 2026. https://mongevity.science/cancer/2026/11/lung-cancer-cd73-cd39-pathway-treatment-selection/
Vancouver
Mongevity Desk. Lung cancer study maps where CD73 and CD39 sit in tumors [Internet]. Mongevity; 2026 Nov 22 cited 2026 Nov 22]. Available from: https://mongevity.science/cancer/2026/11/lung-cancer-cd73-cd39-pathway-treatment-selection/
APA
Mongevity Desk. (2026, November 22). Lung cancer study maps where CD73 and CD39 sit in tumors. Mongevity. https://mongevity.science/cancer/2026/11/lung-cancer-cd73-cd39-pathway-treatment-selection/
For your website
<a href="https://mongevity.science/cancer/2026/11/lung-cancer-cd73-cd39-pathway-treatment-selection/">Lung cancer study maps where CD73 and CD39 sit in tumors</a>

Free to share or quote with credit and a link.

Questions and answers

What are CD73 and CD39?
They are parts of a pathway found in lung tumors. Recent trials tested antibodies that block CD73 along with PD-L1 drugs in some people with non-small cell lung cancer.
Does this study change lung cancer treatment today?
No. It is lab research on tumor samples and cultured cells. It maps where the pathway is found, but it does not test whether this helps choose treatments.
Which lung tumors had more of the pathway?
It was found more in lung adenocarcinomas with high PD-L1 and many effector T cells, or without STK11 and KEAP1 gene changes.
Did chemotherapy and radiation affect it?
In the lab-grown cancer cells, radio-chemotherapy changed how much CD73 the cells carried. The study describes the change as differential, not the same in every case.

Sources

  1. Cell Rep Med: The CD39/CD73 adenosinergic pathway is increased by proinflammatory states and modified by chemo-radiation in human non-small cell lung cancer (PMID 43003091 · DOI 10.1016/j.xcrm.2026.103139) · 2026-11-22

More on this story

Report an error